Get started
Author

SriVidya Yarlagadda

Observed name: Sri Vidya Yarlagadda
Institution: McLaren Health Care
ORCID: 0009-0002-2064-2038
Observed ORCID: 0009-0002-2064-2038
OpenAlex ID: A5043840443
Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al. · Cancer Immunology Research · 2
Data from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al.
Table S1 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al.
Table S2 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al.
Figure S2 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al.
Figure S1 from Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance)
2026 · Alvin Liu, Courtney Johnson, et al.
Abstract 5036: Induction of highly efficacious anti-tumor activity and modulation of tumor microenvironment: Cell-free off the shelf therapeutic modality
2019 · Archana Thakur, SriVidya Yarlagadda, et al. · Clinical Research (Excluding Clinical Trials)
Abstract 5036: Induction of highly efficacious anti-tumor activity and modulation of tumor microenvironment: Cell-free off the shelf therapeutic modality
2019 · Archana Thakur, SriVidya Yarlagadda, et al. · Cancer Research
Works count: 8
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type